Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 1
1948 2
1949 3
1951 2
1952 5
1954 1
1955 1
1957 1
1959 1
1962 1
1963 1
1964 4
1965 1
1966 3
1967 1
1968 4
1969 4
1970 4
1971 3
1972 1
1974 1
1975 1
1976 1
1977 1
1978 2
1979 4
1981 4
1982 1
1983 4
1984 6
1985 5
1986 8
1987 11
1988 14
1989 10
1990 15
1991 16
1992 16
1993 28
1994 16
1995 16
1996 18
1997 26
1998 24
1999 21
2000 21
2001 18
2002 25
2003 17
2004 21
2005 25
2006 27
2007 24
2008 31
2009 32
2010 39
2011 36
2012 36
2013 39
2014 37
2015 30
2016 24
2017 20
2018 23
2019 7
2020 4
2021 4
2022 2
2023 3
2024 4
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

832 results

Results by year

Filters applied: . Clear all
Page 1
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.
INSIGHT START Study Group; Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, Avihingsanon A, Cooper DA, Fätkenheuer G, Llibre JM, Molina JM, Munderi P, Schechter M, Wood R, Klingman KL, Collins S, Lane HC, Phillips AN, Neaton JD. INSIGHT START Study Group, et al. Among authors: cooper da. N Engl J Med. 2015 Aug 27;373(9):795-807. doi: 10.1056/NEJMoa1506816. Epub 2015 Jul 20. N Engl J Med. 2015. PMID: 26192873 Free PMC article. Clinical Trial.
Rational design of a JAK1-selective siRNA inhibitor for the modulation of autoimmunity in the skin.
Tang Q, Fakih HH, Zain Ui Abideen M, Hildebrand SR, Afshari K, Gross KY, Sousa J, Maebius AS, Bartholdy C, Søgaard PP, Jackerott M, Hariharan V, Summers A, Fan X, Okamura K, Monopoli KR, Cooper DA, Echeverria D, Bramato B, McHugh N, Furgal RC, Dresser K, Winter SJ, Biscans A, Chuprin J, Haddadi NS, Sherman S, Yıldız-Altay Ü, Rashighi M, Richmond JM, Bouix-Peter C, Blanchard C, Clauss A, Alterman JF, Khvorova A, Harris JE. Tang Q, et al. Among authors: cooper da. Nat Commun. 2023 Nov 4;14(1):7099. doi: 10.1038/s41467-023-42714-4. Nat Commun. 2023. PMID: 37925520 Free PMC article.
RNAi-based modulation of IFN-γ signaling in skin.
Tang Q, Sousa J, Echeverria D, Fan X, Hsueh YC, Afshari K, MeHugh N, Cooper DA, Vangjeli L, Monopoli K, Okamura K, Biscans A, Clauss A, Harris JE, Khvorova A. Tang Q, et al. Among authors: cooper da. Mol Ther. 2022 Aug 3;30(8):2709-2721. doi: 10.1016/j.ymthe.2022.04.019. Epub 2022 Apr 27. Mol Ther. 2022. PMID: 35477658 Free PMC article.
NOVA2 regulates neural circRNA biogenesis.
Knupp D, Cooper DA, Saito Y, Darnell RB, Miura P. Knupp D, et al. Among authors: cooper da. Nucleic Acids Res. 2021 Jul 9;49(12):6849-6862. doi: 10.1093/nar/gkab523. Nucleic Acids Res. 2021. PMID: 34157123 Free PMC article.
Reply.
Zaunders JJ, Cunningham PH, Kaufmann GR, Cooper DA. Zaunders JJ, et al. Among authors: cooper da. J Infect Dis. 2000 Apr;181(4):1519-20. doi: 10.1086/315363. J Infect Dis. 2000. PMID: 10762591 No abstract available.
Integrating HIV prevention into practice.
Mathers BM, Cooper DA. Mathers BM, et al. Among authors: cooper da. JAMA. 2014 Jul 23-30;312(4):349-50. doi: 10.1001/jama.2014.8606. JAMA. 2014. PMID: 25038352 No abstract available.
Managing first-line failure.
Cooper DA. Cooper DA. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19489. doi: 10.7448/IAS.17.4.19489. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25393998 Free PMC article.
Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials.
Steigbigel RT, Cooper DA, Teppler H, Eron JJ, Gatell JM, Kumar PN, Rockstroh JK, Schechter M, Katlama C, Markowitz M, Yeni P, Loutfy MR, Lazzarin A, Lennox JL, Clotet B, Zhao J, Wan H, Rhodes RR, Strohmaier KM, Barnard RJ, Isaacs RD, Nguyen BY; BENCHMRK Study Teamsa. Steigbigel RT, et al. Among authors: cooper da. Clin Infect Dis. 2010 Feb 15;50(4):605-12. doi: 10.1086/650002. Clin Infect Dis. 2010. PMID: 20085491 Free PMC article. Clinical Trial.
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.
Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarin A, Clotet B, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD, Teppler H, Nguyen BY; BENCHMRK Study Teams. Cooper DA, et al. N Engl J Med. 2008 Jul 24;359(4):355-65. doi: 10.1056/NEJMoa0708978. N Engl J Med. 2008. PMID: 18650513 Free article. Clinical Trial.
832 results